Kirkland Advises Linden Capital Partners on its Acquisition of Alcresta Therapeutics
Kirkland & Ellis represented Linden Capital Partners, a Chicago-based private equity firm focused exclusively on the healthcare industry, on its acquisition of Alcresta Therapeutics, Inc., a leader in commercializing novel enzyme-based products designed to address challenges faced by patients living with gastrointestinal disorders and rare diseases.
The Kirkland team was led by corporate partners Brett Nelson and Robert Wilson; tax partner Chris Worek; and debt finance partners Thomas Dobleman and Daniel Schwimmer.
